News

News 13.05.2022 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2022 (GLOBE NEWSWIRE) --  Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its interim management statement for the quarter ending...

News 11.05.2022 Zurich-Schlieren, Switzerland and Avellino, Italy, May 11, 2022 – Diagnostica Medica of Mercogliano (Avellino), Italy, and Proteomedix, the Swiss cancer diagnostics company, announced today that Proclarix®, a new blood test for the management of prostate cancer patients, has been introduced in the routine of the laboratory that is part of...

News 03.05.2022 BASEL, Switzerland and ZURICH-SCHLIEREN, Switzerland, May 03, 2022 (GLOBE NEWSWIRE) -- The Swiss Biotech Association and Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Molecular Partners’ Chief Executive Officer Patrick Amstutz, Ph.D.,...

Events, External events
Event date: 07.06.2022 7 & 8 June 2022, ETH Zurich, HG E7 & E5 www.personalizedhealth.ch   This third edition of the conference will once more bring together experts from a variety of disciplines to explore present and future directions in the field of personalized health technologies. We aim to meet challenges in clinical bioinformatics, chemical...

News 28.04.2022 Schlieren (Zurich), Switzerland, April 27, 2022 – Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, today provided a first-quarter business update, showing a significant acceleration in product sales of its Medical devices segment. Medical devices sales increased 102% in Q1 2022 compared to Q1 2021. The U.S....